ZYUS Life Sciences (TSXV:ZYUS) ROCE % : -278.16% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ZYUS Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2023 was -278.16%.

ZYUS Life Sciences ROCE % Historical Data

The historical data trend for ZYUS Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ZYUS Life Sciences ROCE % Chart

ZYUS Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-38.60

-114.60

ZYUS Life Sciences Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial				-35.71	-24.78	-39.23	-26.48	-278.16

ZYUS Life Sciences ROCE % Calculation

ZYUS Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-45.167	/	( ( (64.712 - 14.268)	+	(41.627 - 13.244) )	/ 2 )
	=	-45.167	/	( (50.444	+	28.383)	/ 2 )
	=	-45.167	/	39.4135
	=	-114.60 %

ZYUS Life Sciences's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-120.252	/	( ( (71.833 - 13.753)	+	(41.627 - 13.244) )	/ 2 )
	=	-120.252	/	( ( 58.08	+	28.383 )	/ 2 )
	=	-120.252	/	43.2315
	=	-278.16 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

ZYUS Life Sciences (TSXV:ZYUS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ZYUS Life Sciences ROCE % Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ZYUS Life Sciences (TSXV:ZYUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ZLSCF:USA

Address

407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8

Website

https://www.zyus.com

ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.

Executives

John Michael Hyshka

Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines